Related Experiment Video
Updated: Jul 1, 2025
08:55
Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing
Published on: January 20, 2023
11.2K
Recent advances in nanoparticulate RNA delivery systems
Jacob Witten1,2,3, Yizong Hu2, Robert Langer1,2,3,4,5,6
1Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
Summary
Advancements in nanoparticle-based RNA delivery, including mRNA vaccines and siRNA therapies, are expanding treatment options. New materials and cargo designs improve targeting to various organs and cells, enhancing efficacy for gene therapy and vaccines.
Area of Science:
- Biotechnology
- Nanomedicine
- Molecular Therapy
Background:
- Nanoparticle-based RNA delivery has seen significant progress, exemplified by mRNA vaccines for SARS-CoV-2 and liver-targeted siRNA therapies.
- Recent approvals highlight the therapeutic potential and growing clinical relevance of RNA delivery systems.
Purpose of the Study:
- To review the preclinical and clinical advancements in next-generation RNA delivery therapies.
- To explore improvements in RNA cargo design, material science for targeted delivery, and modulation of immune responses.
- To discuss the current landscape of RNA delivery clinical trials and future directions.
Main Methods:
- Discussion of innovations in RNA cargo design, including circularization and untranslated region optimization.
- Review of new materials enabling targeted delivery to extrahepatic sites like the lungs and spleen.
- Analysis of strategies for ligand conjugation to achieve organ- and cell-specific targeting.
- Examination of approaches to modulate immune responses for enhanced vaccine immunogenicity or reduced gene therapy reactogenicity.
Main Results:
- Improved mRNA expression through optimized RNA cargo design.
- Enhanced delivery to extrahepatic targets, enabling potential pulmonary gene therapy and improved cancer vaccines.
- Development of targeted delivery systems for specific organs and cell types via ligand conjugation.
- Strategies to balance immunogenicity for vaccines and minimize immune responses for gene therapies.
Conclusions:
- Next-generation RNA delivery therapies show promise for diverse applications, from vaccines to gene therapies.
- Continued innovation in materials, cargo design, and immune response modulation is crucial for future therapeutic success.
- The expanding clinical trial landscape indicates a robust pipeline for RNA-based treatments across various diseases.
